NCT06510452View on ClinicalTrials.gov

Antibiotic Prophylaxis in Metabolic Bariatric Surgery

NANot yet recruitingINTERVENTIONAL
Enrollment

3,352

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

April 1, 2026

Conditions
Antibiotic ReactionWound Infection SuperficialWound Infection DeepBariatric Surgery CandidateComplication,Postoperative
Interventions
DRUG

2000 mg of Cefazolin

receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.

DRUG

500 mg of Metronidazole IV

receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.

DRUG

NACL 0.9% 100 ml

receive 100 ml NACL0.9% without any antibiotics in it.

Trial Locations (2)

21531

Madina Women's Hospital, Alexandria

Unknown

WeightWorks clinics, Amersfoort

All Listed Sponsors
lead

General Committee of Teaching Hospitals and Institutes, Egypt

OTHER_GOV

NCT06510452 - Antibiotic Prophylaxis in Metabolic Bariatric Surgery | Biotech Hunter | Biotech Hunter